|
Serial plasma and CSF cell-free tumor DNA (cf-tDNA) tracking in diffuse midline glioma patients undergoing treatment with ONC201. |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
Research Funding - Genentech/Roche |
| |
|
Employment - Chimerix; Oncoceutics |
Leadership - Chimerix; Oncoceutics |
Stock and Other Ownership Interests - Chimerix; Chimerix; Oncoceutics; Oncoceutics |
Patents, Royalties, Other Intellectual Property - ONC201-related patents; ONC201-related patents |
Travel, Accommodations, Expenses - Oncoceutics; Oncoceutics; Oncoceutics; Oncoceutics; Oncoceutics |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |